icosapent ethyl / Generic mfg. - LARVOL DELTA

Assessing Omega-3 Therapy and Its Cardiovascular Benefits: What About Icosapent Ethyl? A Systematic Review and Meta-Analysis. (PubMed, Pharmaceuticals (Basel)) - "The limitations of the reviewed studies may include small sample sizes, varying outcomes, and a small duration of interventions. Future clinical trials with similar outcomes, sample sizes, and intervention durations must be designed, and updated meta-analyses must be published in the following years to fully assess the effects of IPE as a lipid-lowering and cardiovascular protector drug."

Journal • Retrospective data • Review • Atherosclerosis • Cardiovascular

Resolving the Metabolic Puzzle, Tirzepatide's Multifaceted Benefits in Partial Lipodystrophy (ENDO 2025) - "Metreleptin is an approved therapy for GLD, but there are no FDA-approved treatments for PLD...Medications included insulin, metformin XR 2000 mg daily, empagliflozin 25 mg daily, rosuvastatin 20 mg daily, icosapent ethyl 4 grams daily, and fenofibrate 160 mg daily... The patient exhibited profound and multifaceted metabolic improvement following initiation of tirzepatide treatment. These improvements were much greater than previously reported with GLP-1 receptor agonists in PL, suggesting a unique role for GIP receptor agonism in addressing the complex metabolic dysregulation associated with this disorder. The observed clinical benefits, including improved glycemic control, triglyceride improvement, reduced insulin dependence, and improved steatosis have significant implications for the management of this complex and challenging condition."

Dyslipidemia • Genetic Disorders • Hepatology • Hypertriglyceridemia • Hypoglycemia • Lipodystrophy • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Pancreatitis • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Giant Pancreatic Pseudocyst as a complication of Hypertriglyceridemia-Induced Pancreatitis (ENDO 2025) - "On day tenth, given clinical and biochemical improvement and a multidisciplinary team discussion, patient was discharged on metformin, fenofibrate, atorvastatin, pioglitazone, and vascepa, with plan for GI follow-up for possible necrosectomy. This case reports rare occurrence of HTG-induced necrotizing pancreatitis with the formation of giant pancreatic pseudocyst. It also illustrates the importance of timely intervention and proper management of severe hypertriglyceridemia, to reduce the risk of complications including necrotizing pancreatitis and pseudocyst. Long-term management should be focused on alleviating the effects of metabolic syndrome by addressing related factors like diabetes and obesity."

Diabetes • Dyslipidemia • Genetic Disorders • Hypertriglyceridemia • Metabolic Disorders • Obesity • Pain • Pancreatitis • Severe Hypertriglyceridemia

Impact of GLP-1 Analogs vs. Lipid Lowering Agents on Risk for Acute Pancreatitis in Hypertriglyceridemia: A TriNetX Analysis (ENDO 2025) - "There were 21,106 patients receiving treatment with a GLP-1 analog (Cohort A) and 296,961 patients taking lipid lowering agents which we defined as atorvastatin, rosuvastatin, pravastatin, simvastatin, fenofibrate, ezetimibe, icosapent ethyl, evolocumab (Cohort B). Ongoing research is essential to understand the long-term outcomes of GLP-1 analog therapy.*. .*"

Dyslipidemia • Genetic Disorders • Hypertriglyceridemia • Obesity • Pancreatitis • Severe Hypertriglyceridemia

Evinacumab as an Effective Treatment Option for Refractory Hypertriglyceridemia (ENDO 2025) - "Despite using atorvastatin 80 mg daily, fenofibrate 162 mg daily, icosapent ethyl 2 g twice daily, and evolocumab 140 mg every 2 weeks, she continued to have hypertriglyceridemia. Evinacumab may be an effective alternative agent for the management of chronic hypertriglyceridemia based on the robust effects seen in our patient. Future research is needed to explore evinacumab's therapeutic targets beyond LDL-C to better modify risk factors for atherosclerosis, as well as CAV progression in heart transplant recipients.*. .*"

Atherosclerosis • Cardiomyopathy • Cardiovascular • Diabetes • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Hypertriglyceridemia • Metabolic Disorders • Pancreatitis • Severe Hypertriglyceridemia • Type 2 Diabetes Mellitus • ANGPTL3 • APOB

Breaking the Triglyceride Barrier: A Case of Severe Hypertriglyceridemia Management (ENDO 2025) - "Pharmacologic therapy included continuation of rosuvastatin 40 mg, fenofibrate 160 mg, and ezetimibe 10 mg. Patient was also started on Icosapent ethyl 2 g twice daily and Levothyroxine (LTX) was increased from 125 mcg to 150 mcg due to an elevated TSH level of 10.4 µIU/mL with a free T4 of 1.0 ng/dL...The patient was also prescribed evolocumab, but insurance restrictions required specialist approval...Further research is needed to assess long-term outcomes and the role of emerging therapies in severe HTG management.*. .*"

Clinical • Cardiovascular • Dyslipidemia • Endocrine Disorders • Hypertension • Hypertriglyceridemia • Obesity • Pancreatitis • Severe Hypertriglyceridemia

BEYOND STATINS: THE COMBINED IMPACT OF PCSK9 INHIBITORS AND ICOSAPENT ETHYL ON CORONARY PLAQUE THROUGH SERIAL CORONARY CT ANGIOGRAPHY - Venkat Sanjay Manubolu (ACC 2025) - "The addition of PCSK9 inhibitors and Icosapent ethyl to statin therapy enhances plaque reduction and stabilization in CAD patients. This study underscores the value of serial cardiac CT in monitoring plaque dynamics and guiding therapy optimization. Further research is needed on dynamic quantitative plaque changes and triple therapy."

Cardiovascular • Coronary Artery Disease

IMPACT OF ICOSAPENT ETHYL IN COMBINATION WITH STATINS ON MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH DYSLIPIDEMIA: A META-ANALYSIS - Mario Cesar Torres Chavez (ACC 2025) - "IPE, when added to statins, reduces major cardiovascular events but does not lower cardiovascular mortality, making it effective for secondary prevention."

Combination therapy • Retrospective data • Cardiovascular • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders • Myocardial Infarction

ALLIED HEALTH PROFESSIONAL OPTIMIZATION OF DYSLIPIDEMIA TREATMENT: TOWARD OPTIMAL CARDIOVASCULAR RISK REDUCTION - Jenny Gao-Kang (ACC 2025) - "Targeted screening and optimization by allied health professionals improves blood lipid profile."

Cardiovascular • Dyslipidemia • Metabolic Disorders

IMPACT OF ICOSAPENT ETHYL ON LIPID PROFILE IN HIGH-RISK CARDIOVASCULAR PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS - Hashim Mohamed Siraj (ACC 2025) - "IPE significantly reduces TG, VLDL-C, and non-HDL-C levels, particularly at a 4000 mg/day dose. It has no significant effect on LDL-C and HDL-C levels."

Retrospective data • Review • Cardiovascular

ADDITION OF EICOSAPENTAENOIC ACID TO A GLP-1 AGONIST ENHANCED EXPRESSION OF DETOXIFICATION PROTEINS IN ENDOTHELIAL CELLS DURING INFLAMMATION IN VITRO - Samuel C. Sherratt (ACC 2025) - "EPA administered as icosapent ethyl reduced cardiovascular (CV) events in high-risk patients (REDUCE-IT). In ECs, EPA enhanced expression of ROS detoxification proteins and related pathway in combination with liraglutide. These proteins included HO-1, NQO1, and SRXN1 that may exert atheroprotective effects. These beneficial actions of a GLP-1RA on protein expression when combined with EPA during inflammation may enhance CV protection."

Preclinical • Cardiovascular • Inflammation • HMOX1 • NQO1

MORE RAPID OXIDATION OF LIPOPROTEIN(A)-ENRICHED PLASMA COMPARED TO SMALL DENSE- AND TRIGLYCERIDE-RICH LIPOPROTEINS IS LIMITED BY EICOSAPENTAENOIC ACID - R. P. Mason (ACC 2025) - "The omega-3 fatty acid EPA delivered as icosapent ethyl (4 g/d) reduced CV events in high-risk patients, including those with elevated Lp(a) (REDUCE-IT)... Lp(a)-enriched plasma underwent more rapid oxidation than other ApoB-containing lipoproteins tested, likely due to oxidized phospholipid content. EPA dose-dependently inhibited oxidation in all lipoproteins tested, especially Lp(a) enriched plasma. The potent inhibition of Lp(a) oxidation by EPA may contribute to the benefit observed in REDUCE-IT, including those subjects with elevated Lp(a) levels."

Cardiovascular • APOB

Cross-Sectional analysis of demographic and clinical characteristics of patients in the United States using icosapent ethyl. (PubMed, Front Cardiovasc Med) - "Patients taking IPE had characteristics consistent with its indication, including well-controlled LDL-C levels with statin use. The higher triglyceride levels before IPE initiation suggest that IPE may be underutilized in patients at high risk for CV events; however, future studies are needed."

Journal • Cardiovascular • Coronary Artery Disease • Diabetes • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders • Severe Hypertriglyceridemia

Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist (GlobeNewswire) - "In this analysis, researchers analyzed rates of oxidation for Lp(a)-enriched plasma to other atherogenic particles, including enriched small dense LDL (sdLDL), LDL, or triglyceride (TG)-rich lipoproteins (VLDL) with and without the introduction of EPA at a pharmacologic concentration....An elevated Lp(a) level is known to increase CV risk. New data from this analysis show that EPA dose-dependently inhibited oxidation in all lipoproteins tested, especially Lp(a) enriched human plasma....with emerging therapeutic approaches to address residual cardiovascular risk there is added value in exploring the combination of proven therapies, in this case EPA and GLP-1 receptor agonist, with complementary or additive protective mechanisms that may potentially play a role in further reducing cardiovascular risk on top of the statin therapy."

Preclinical • Cardiovascular

Comparison of product label vs real-world safety data from branded icosapent ethyl users: A select analysis utilizing MarketScan data. (PubMed, J Clin Lipidol) - "IPE may be well tolerated in real-world settings."

Journal • Real-world evidence • Atrial Fibrillation • Cardiovascular • Constipation • Gastroenterology • Gastrointestinal Disorder

Serum Lipids, Inflammation, and the Risk of Atrial Fibrillation: Pathophysiological Links and Clinical Evidence. (PubMed, J Clin Med) - "Lipoprotein (a), adiposity, and inflammation seem to be the main drivers of AF; in contrast, low-density lipoproteins, high-density lipoproteins and triglycerides are not directly involved in AF onset. The present review aimed to describe the pathophysiological link between dyslipidemia and AF, the efficacy of lipid-lowering therapies in atherosclerotic cardiovascular disease (ASCVD) patients with and without AF, and the impact of lipid-lowering therapies on AF incidence."

Journal • Review • Atherosclerosis • Atrial Fibrillation • Cardiovascular • Dyslipidemia • Inflammation • Metabolic Disorders • Obesity

ARTCAP: Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP) (clinicaltrials.gov) - P4 | N=0 | Withdrawn | Sponsor: University of Louisville | N=200 ➔ 0 | Trial completion date: Jan 2029 ➔ Jan 2025 | Recruiting ➔ Withdrawn | Trial primary completion date: Jan 2029 ➔ Jan 2025

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Myocardial Infarction

Amarin Marks Key Milestone for VASCEPA/VAZKEPA (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering (GlobeNewswire) - P3 | N=8179 | REDUCE-IT (NCT01492361) | Sponsor: Amarin Pharma Inc. | "IPE, which is the active ingredient in VASCEPA, significantly reduced the primary composite endpoint of cardiovascular events by 34% among patients with very well-controlled LDL-C (<55mg/dL)...Icosapent ethyl significantly reduced the primary composite end point by 34% among patients with very well-controlled LDL-C. The primary outcome rate among patients with LDL-C <55 mg/dL was 16.2% in the IPE group and 22.8% in the placebo group, HR 0.66 (95% CI 0.50-0.87; P=0.003). Findings were consistent in the LDL-C ≥55 mg/dL subgroup, with rates of 17.4% in the IPE group and 21.9% in the placebo group, HR 0.76 (95% CI 0.69-0.85; P<0.0001). No significant interaction between baseline LDL-C and treatment group was observed."

P3 data • Cardiovascular • Hypertriglyceridemia

Amarin Receives National Reimbursement for VAZKEPA in Austria (GlobeNewswire) - "Amarin Corporation plc...today announced that Austria’s Health Authorities have approved VAZKEPA for national reimbursement to reduce the risk of cardiovascular events in adult statin-treated patients with elevated triglycerides and established cardiovascular disease (eCVD). As of April 1st 2025, VAZKEPA will be included in Austria’s Code of Reimbursement (EKO)."

Reimbursement • Cardiovascular

Idiopathic and Metabolic Triggers Leading to Recurrent Acute Pancreatitis in a 30-Year-Old Woman. (PubMed, Hosp Pharm) - "Tailoring interventions, such as switching diabetes medications (from semaglutide to dapagliflozin) and emphasizing TG management through gemfibrozil, atorvastatin, and icosapent ethyl, proved essential in stabilizing her condition. The patient's case serves as a reminder of the multiple potential causes of pancreatitis and the need for ongoing monitoring to prevent further complications."

Journal • Diabetes • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders • Pancreatitis • Type 2 Diabetes Mellitus

Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. (PubMed, J Am Heart Assoc) - P3 | "Among statin-treated patients with elevated triglycerides and high cardiovascular risk, icosapent ethyl reduced the rate of cardiovascular end points irrespective of baseline LDL-C, including among eligible patients with optimal LDL-C control."

Clinical • Journal • Cardiovascular • Dyslipidemia • Hypertriglyceridemia • Myocardial Infarction

Hyperlipidemic Abdominal Crisis: A Unique Presentation of Isolated Severe Hypertriglyceridemia. (PubMed, Cureus) - "After consultation with Endocrinology, the patient was admitted for an insulin infusion with glucose-containing maintenance fluids to help treat the very severe hypertriglyceridemia. The patient was discharged in good condition on hospital day 3 with triglyceride levels down to 405 mg/dL and prescribed a new oral agent, Icosapent ethyl at 2 g orally daily. Clinicians evaluating patients for acute abdominal complaints should be alert to the possible diagnosis of HLAC given the potential for deterioration to pancreatitis and concomitant complications. Prompt management with an insulin infusion or plasmapheresis along with appropriate consultation with specialists is crucial to mitigate the risk of adverse outcomes in this rare abdominal emergency."

Journal • Dyslipidemia • Endocrine Disorders • Hypertriglyceridemia • Pancreatitis • Severe Hypertriglyceridemia • HLA-C

Acquired Generalized Lipodystrophy as an Adverse Event of Combined Immune Checkpoint Inhibitor Therapy. (PubMed, JCEM Case Rep) - "We present a 48-year-old female with recurrent malignant melanoma who underwent 23 cycles of nivolumab, a PD-1 inhibitor, and 11 cycles of combined cytotoxic T lymphocyte associated antigen 4 (CTLA-4) inhibitor and PD-1 inhibitor ipilimumab-nivolumab. Treatment included insulin (average total daily dose 0.13-0.26 Units/kg/day) and a combination of lipid-lowering therapy (statins, fenofibrate, icosapent ethyl), which led to marked improvement in triglycerides and symptoms. This case further underscores the emerging challenges with endocrinopathies associated with checkpoint inhibitors."

Adverse events • Checkpoint inhibition • Journal • Diabetes • Dyslipidemia • Endocrine Disorders • Hypertriglyceridemia • Lipodystrophy • Melanoma • Metabolic Disorders • Oncology • Severe Hypertriglyceridemia • Solid Tumor • LEP

Type 2 Diabetes Mellitus with Diabetic Ketoacidosis, Hypertriglyceridemia, and Acute Pancreatitis in an Adolescent with Autism Spectrum Disorder and Pancreatic Divisum. (PubMed, Cureus) - "Following a temporary initial recovery, the patient experienced worsening obesity and was started on metformin and icosapent ethyl to manage recurrent T2DM and HTG. In this case, the development of T2DM was considered to have been primarily associated with ASD, which subsequently led to DKA, HTG, and AP, with pancreatic divisum believed to be an additional predisposing factor contributing to these conditions. To the best of our knowledge, there have been no previous reports of T2DM associated with DKA, HTG, AP, ASD, and pancreatic divisum."

Journal • Autism Spectrum Disorder • CNS Disorders • Developmental Disorders • Diabetes • Dyslipidemia • Gastrointestinal Disorder • Genetic Disorders • Hepatology • Hypertriglyceridemia • Metabolic Disorders • Obesity • Pain • Pancreatitis • Pediatrics • Psychiatry • Type 2 Diabetes Mellitus

BE-001-2024: CreNeuroS™️CNS Fish Oil Plus Softgels Compared to Vascepa® Capsules and Deplin® Capsules in a Pharmacokinetic, Single Dose Evaluation on Healthy Adult Human Subjects Under Fasting Conditions (clinicaltrials.gov) - P=N/A | N=14 | Enrolling by invitation | Sponsor: Sichuan Credit Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Enrolling by invitation

Enrollment open